Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KT-474 · SAR-444656

Small molecule · developed by Kymera Therapeutics

Phase 1 Most advanced trial (none active)
KYMR Developer
1 Registered trials

What is KT-474?

KT-474 (also known as SAR-444656) is an oral tablet studied in healthy volunteers, atopic dermatitis and hidradenitis suppurativa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-444656
Drug type
Small molecule
Therapy area
Dermatology, Immunology
Developer
Kymera Therapeutics, Inc. (KYMR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
2SXR65P7E3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04772885 Phase 1 Healthy Volunteer Completed KYMR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic DermatitisHealthy VolunteerHidradenitis Suppurativa

More from Kymera Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.

Follow KYMR, the company behind KT-474

See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYMR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.